CJC 1295 + Ipamorelin Blend

The CJC-1295 + Ipamorelin blend combines two complementary growth-hormone secretagogues in a single vial: CJC-1295, a GHRH (growth-hormone-releasing-hormone) analog, and ipamorelin, a selective GHRP / ghrelin-receptor agonist. In research, a GHRH and a GHRP act on distinct pituitary receptors and together produce a synergistic release of growth hormone greater than either alone.

CJC-1295 raises the baseline of GH/IGF-1 signaling, while ipamorelin adds a clean, selective GH pulse without significantly raising cortisol or prolactin. Supplied as research-grade material for laboratory use only.

• Synergistic GH release from combined GHRH + GHRP signaling
• GHRH-receptor and GHS-R1a (ghrelin) pharmacology
• GH–IGF-1 axis modulation and pulsatility
• Body-composition and metabolic research models
• Selective GH secretion without raising cortisol or prolactin
• Comparison of continuous vs pulsatile GH-secretagogue protocols

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

GHRH + GHRP research blend. References often use ~100–300 mcg of each per dose, 1–2×/day (frequently before sleep, fasted). Protocols vary by study.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Adverse effects reported in the research and clinical literature for GH-secretagogue peptides (CJC-1295 and ipamorelin) include:

• Injection-site reactions (redness, itching, swelling)
• Transient facial flushing, headache or dizziness
• Water retention or mild edema
• Tingling or numbness in the extremities
• Fatigue or drowsiness, often shortly after a dose
• Increased appetite (ghrelin-receptor activity of ipamorelin)
• Elevated GH/IGF-1 with prolonged exposure, with possible effects on glucose tolerance

Reported in the research and clinical literature; not a clinical safety profile. Effects vary by study, dose and preparation. Research use only.

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.

1. Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. doi.org
2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. academic.oup.com